As opposed to the conventional black-box approach, our transparent and collaborative approach enables transfer of capabilities to our client organizations
Our short-term pilot engagements focus on providing AI based solutions that cater to specific needs of pharma enterprises. These engagements provide an opportunity for pharma companies to gain a deeper understanding of AI capabilities and opportunities to collaborate on long-term relationships.
e.g., Building a protein-ligand affinity prediction model for a particular protein family
Our outcome based projects enable pharma companies to minimize risk while experimenting how their most complex problems can be addressed using the latest state of art in AI. This enables pharma companies to pick any problem across any step of the value chain as opposed to finding a problem that suits our capabilities.
e.g., Building a NLP based tool to extract specific information such as reactions, figures and diagrams from literature
We also take up development of products and services that have a long-term and wide range of applications for the industry. As these may require a marriage of our AI capabilities with private data of pharma companies, we are open to a risk sharing model that is mutually beneficial.
e.g., Building a neoepitope prediction model using gene sequencing data